A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.
【저자키워드】 COVID-19, Multiple sclerosis (MS), disease-modifying therapies (DMTs), 【초록키워드】 coronavirus disease, coronavirus, SARS-CoV2, therapy, severe COVID-19, multiple sclerosis, COVID-19 pandemic, Infection, risk, Patient, Evidence, severe disease, acute respiratory syndrome, higher risk, hazard, susceptible, Course, shown, develop, treated, suggested, immunosuppressive drug, 【제목키워드】 Strategy, Multiple, controlling,